CBAY - Cymabay Therapeutics Inc Stock Price, Fair Value and News

32.48USD Market Closed

Market Summary

USD32.48

Market Closed

CBAY Stock Price

View Fullscreen

CBAY RSI Chart

CBAY Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

-35.36

Price/Sales (Trailing)

119.92

Price/Free Cashflow

-51.06

CBAY Price/Sales (Trailing)

CBAY Profitability

Return on Equity

-36.05%

Return on Assets

-24.24%

Free Cashflow Yield

-1.96%

CBAY Fundamentals

CBAY Revenue

Revenue (TTM)

31.1M

Rev. Growth (Yr)

-99.79%

CBAY Earnings

Earnings (TTM)

-105.4M

Earnings Growth (Yr)

-57.33%

Earnings Growth (Qtr)

-23.67%

Breaking Down CBAY Revenue

Last 7 days

0.1%

Last 30 days

0.9%

Last 90 days

40.7%

Trailing 12 Months

255.0%

How does CBAY drawdown profile look like?

CBAY Financial Health

Current Ratio

10.96

CBAY Investor Care

Shares Dilution (1Y)

35.48%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	31.1M
2022	0	0	0	0
2021	0	0	0	0
2017	5.4M	7.7M	4.8M	10.0M
2012	12.1M	9.1M	6.1M	3.0M
2011	0	0	0	15.1M
2010	0	0	0	800.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CEO	Mr. Sujal A. Shah
WEBSITE	cymabay.com
INDUSTRY	Biotechnology
EMPLOYEES	60

Cymabay Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cymabay Therapeutics Inc? What does CBAY stand for in stocks?

CBAY is the stock ticker symbol of Cymabay Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cymabay Therapeutics Inc (CBAY)?

As of Mon Mar 25 2024, market cap of Cymabay Therapeutics Inc is 3.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CBAY stock?

You can check CBAY's fair value in chart for subscribers.

Is Cymabay Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CBAY is over valued or under valued. Whether Cymabay Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cymabay Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CBAY.

What is Cymabay Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 25 2024, CBAY's PE ratio (Price to Earnings) is -35.36 and Price to Sales (PS) ratio is 119.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CBAY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cymabay Therapeutics Inc's stock?

In the past 10 years, Cymabay Therapeutics Inc has provided 0.15 (multiply by 100 for percentage) rate of return.